<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39343951</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>01</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">1348-8945</ISSN><JournalIssue CitedMedium="Print"><Volume>52</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>29</Day></PubDate></JournalIssue><Title>Tropical medicine and health</Title><ISOAbbreviation>Trop Med Health</ISOAbbreviation></Journal><ArticleTitle>Exploratory study of antibody titers against SARS-CoV-2 using an indirect immunoperoxidase assay in COVID-19 patients and vaccinated volunteers.</ArticleTitle><Pagination><StartPage>65</StartPage><MedlinePgn>65</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">65</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s41182-024-00635-y</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">A number of antibody test kits for detecting prior SARS-CoV-2 infection and post-immunization status have been commercialized. Indirect immunoperoxidase assay (IIP) is a conventional method to test antibodies. We evaluated the diagnostic accuracy and antibody titer profile of the IIP in COVID-19 and pre- and post-vaccination.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We conducted a hospital-based observational study in Fukushima prefecture, Japan. We enrolled COVID-19 inpatients who tested positive by PCR. We used serum samples collected &gt; 10 years before the pandemic as the negative control. We also included volunteers vaccinated at the hospital. All participants were tested using an IIP with whole-cell antigen of the six SARS-CoV-2 variants isolated in Japan during the epidemic and an IgG ELISA kit. Negative controls and vaccinated volunteers were also tested using a lateral flow assay (LFA) kit. We conducted receiver operating characteristic (ROC) analysis to evaluate diagnostic accuracy and performed logistic regression analysis to explore factors associated with antibody titer.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">We included 146 COVID-19 inpatients, 38 negative controls, and 36 vaccinated volunteers. Most participants had the highest titer for IgG and IgM in the wild type-A antigen among the six variants. The sensitivity, specificity, and accuracy of the IgG ELISA kit were 60.3%, 100%, and 68.5%; of the IIP for IgG with the cutoff titer at 1:80, 82.2%, 94.7%, and 84.8%, respectively. The ROC curves of the ELISA and IIP for IgG were almost identical. In the IgG tests of the 36 volunteers, 35 were positive for ELISA and IIP and 34 for LFA after two vaccinations. IgM titers in the IIP were &lt;  = 1:40 in 114 patients and 32 volunteers after two vaccinations; therefore, the IgM titer is unsuitable for diagnosis. In COVID-19 patients, age, days from disease onset, &gt;  = 7 days after the second vaccination, and immunosuppressants for comorbidity were associated with IgG titer of &gt;  = 1:640 in the IIP.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The diagnostic accuracy of the IIP for detecting IgG antibodies in COVID-19 or after two vaccinations is equivalent to that of an ELISA. Further investigations are required to address the association between antibody titers in the IIP and their protective or harmful effects against COVID-19.</AbstractText><CopyrightInformation>© 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Katoh</LastName><ForeName>Shungo</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-7719-9631</Identifier><AffiliationInfo><Affiliation>Department of General Internal Medicine and Clinical Infectious Diseases, Fukushima Medical University, Fukushima, Japan. shun_5@me.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of General Internal Medicine and Infectious Diseases, Kita-Fukushima Medical Center, Fukushima, Japan. shun_5@me.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Rickettsioses, Kita-Fukushima Medical Center, Fukushima, Japan. shun_5@me.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Imadachi Internal Medicine Clinic, Fukuoka, Japan. shun_5@me.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yasuda</LastName><ForeName>Ikkoh</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of General Internal Medicine and Clinical Infectious Diseases, Fukushima Medical University, Fukushima, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of General Internal Medicine and Infectious Diseases, Kita-Fukushima Medical Center, Fukushima, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Rickettsioses, Kita-Fukushima Medical Center, Fukushima, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kitakawa</LastName><ForeName>Kazuhiro</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Microbiology, Fukushima Prefectural Institute of Public Health, Fukushima, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hamaguchi</LastName><ForeName>Sugihiro</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of General Internal Medicine and Clinical Infectious Diseases, Fukushima Medical University, Fukushima, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of General Internal Medicine, Fukushima Medical University Hospital, Fukushima, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sando</LastName><ForeName>Eiichiro</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of General Internal Medicine and Clinical Infectious Diseases, Fukushima Medical University, Fukushima, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of General Internal Medicine and Infectious Diseases, Kita-Fukushima Medical Center, Fukushima, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Rickettsioses, Kita-Fukushima Medical Center, Fukushima, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>Japan</Country><MedlineTA>Trop Med Health</MedlineTA><NlmUniqueID>101215093</NlmUniqueID><ISSNLinking>1348-8945</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Accuracy</Keyword><Keyword MajorTopicYN="N">Antibody test</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">ELISA</Keyword><Keyword MajorTopicYN="N">Indirect immunoperoxidase assay</Keyword><Keyword MajorTopicYN="N">ROC analysis</Keyword></KeywordList><CoiStatement>The authors declare that they have no competing interest regarding this study.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>30</Day><Hour>0</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>30</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>29</Day><Hour>23</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>29</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39343951</ArticleId><ArticleId IdType="pmc">PMC11439312</ArticleId><ArticleId IdType="doi">10.1186/s41182-024-00635-y</ArticleId><ArticleId IdType="pii">10.1186/s41182-024-00635-y</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>COVID-19 Cumulative Infection Collaborators. Estimating global, regional, and national daily and cumulative infections with SARS-CoV-2 through Nov 14, 2021: a statistical analysis. Lancet. 2022;399(10344):2351–80.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8993157</ArticleId><ArticleId IdType="pubmed">35405084</ArticleId></ArticleIdList></Reference><Reference><Citation>European Centre for Disease Prevention and Control. Considerations for the use of antibody tests for SARS-CoV-2—first update. 10 February 2022. Stockholm: ECDC; 2022.</Citation></Reference><Reference><Citation>Hayden MK, El Mikati IK, Hanson KE, Englund JA, Humphries RM, Lee F, et al. Infectious Diseases Society of America Guidelines on the Diagnosis of COVID-19: serologic testing. Clin Infect Dis. 2024. 10.1093/cid/ciae121.</Citation><ArticleIdList><ArticleId IdType="pubmed">38489670</ArticleId></ArticleIdList></Reference><Reference><Citation>Lisboa Bastos M, Tavaziva G, Abidi SK, Campbell JR, Haraoui LP, Johnston JC, et al. Diagnostic accuracy of serological tests for covid-19: systematic review and meta-analysis. BMJ. 2020;370: m2516.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7327913</ArticleId><ArticleId IdType="pubmed">32611558</ArticleId></ArticleIdList></Reference><Reference><Citation>Koh GC, Maude RJ, Paris DH, Newton PN, Blacksell SD. Diagnosis of scrub typhus. Am J Trop Med Hyg. 2010;82(3):368–70.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2829893</ArticleId><ArticleId IdType="pubmed">20207857</ArticleId></ArticleIdList></Reference><Reference><Citation>Katoh S, Cuong NC, Hamaguchi S, Thuy PT, Cuong DD, Anh LK, et al. Challenges in diagnosing scrub typhus among hospitalized patients with undifferentiated fever at a national tertiary hospital in northern Vietnam. PLoS Negl Trop Dis. 2019;13(12): e0007928.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6917290</ArticleId><ArticleId IdType="pubmed">31805053</ArticleId></ArticleIdList></Reference><Reference><Citation>Suto T. A ten years experience on diagnosis of rickettsial diseases using the indirect immunoperoxidase methods. Acta Virol. 1991;35(6):580–6.</Citation><ArticleIdList><ArticleId IdType="pubmed">1687642</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujita H. Development and optimization of antibody detection assays. In: Ando S, editor. Diagnostics and therapeutics for tick-borne bacterial diseases. MHLW Grant Research Report 201225058A [in Japanese]. Ministry of Health, Labour and Welfare: Tokyo; 2012. p. 95–100.</Citation></Reference><Reference><Citation>Dincer G, Selcuk K, Gokmen Z, A EK. easyROC: an interactive web-tool for ROC curve analysis using R language environment. R J. 2016;8(2):213.</Citation></Reference><Reference><Citation>Meyer B, Torriani G, Yerly S, Mazza L, Calame A, Arm-Vernez I, et al. Validation of a commercially available SARS-CoV-2 serological immunoassay. Clin Microbiol Infect. 2020;26(10):1386–94. 10.1016/j.cmi.2020.06.024.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7320699</ArticleId><ArticleId IdType="pubmed">32603801</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujita S, Kikuchi R, Kitakawa K, Suzuki R, Kashiwabara N, Suzuki K. Genetic analysis of SARS-CoV-2 detected in Fukushima Prefecture by next-generation sequencers. Annu Rep Fukushima Prefectural Inst Public Health. 2023;39:27–31 (in Japanese).</Citation></Reference><Reference><Citation>Kitakawa K, Fujita S, Saito N, Suzuki R, Kashiwabara N, Suzuki K, Kohata H. Genome analysis of SARS-CoV-2 in Fukushima Prefecture (2022). Annu Rep Fukushima Prefectural Inst Public Health. 2024;40:57–64 (in Japanese).</Citation></Reference><Reference><Citation>Hueston L, Kok J, Guibone A, McDonald D, Hone G, Goodwin J, et al. The antibody response to SARS-CoV-2 infection. Open Forum Infect Dis. 2020;7(9):ofaa387. 10.1093/ofid/ofaa387.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7499696</ArticleId><ArticleId IdType="pubmed">32989419</ArticleId></ArticleIdList></Reference><Reference><Citation>Fox T, Geppert J, Dinnes J, Scandrett K, Bigio J, Sulis G, et al.; Cochrane COVID-19 Diagnostic Test Accuracy Group. Antibody tests for identification of current and past infection with SARS-CoV-2. Cochrane Database Syst Rev. 2022;11(11):CD013652. 10.1002/14651858.CD013652.pub2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9671206</ArticleId><ArticleId IdType="pubmed">36394900</ArticleId></ArticleIdList></Reference><Reference><Citation>Sahin U, Muik A, Derhovanessian E, Vogler I, Kranz LM, Vormehr M, et al. COVID-19 vaccine BNT162b1 elicits human antibody and T (H)1 T cell responses. Nature. 2020;586(7830):594–9.</Citation><ArticleIdList><ArticleId IdType="pubmed">32998157</ArticleId></ArticleIdList></Reference><Reference><Citation>Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh C-L, Abiona O, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020;367(6483):1260–3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7164637</ArticleId><ArticleId IdType="pubmed">32075877</ArticleId></ArticleIdList></Reference><Reference><Citation>Lou B, Li TD, Zheng SF, Su YY, Li ZY, Liu W, et al. Serology characteristics of SARS-CoV-2 infection after exposure and post-symptom onset. Eur Respir J. 2020;56(2):2000763. 10.1183/13993003.00763-2020.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7401320</ArticleId><ArticleId IdType="pubmed">32430429</ArticleId></ArticleIdList></Reference><Reference><Citation>Arkhipova-Jenkins I, Helfand M, Armstrong C, Gean E, Anderson J, Paynter RA, et al. Antibody response after SARS-CoV-2 infection and implications for immunity: a rapid living review. Ann Intern Med. 2021;174(6):811–21. 10.7326/M20-7547.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8025942</ArticleId><ArticleId IdType="pubmed">33721517</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>